CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 32 enrolled
Drug / intervention
Omadacycline +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06030219
NCT06030219Phase 1Completed

Microbiome Effect of Omadacycline on Healthy Volunteers

University of Houston·interventional·Posted Sep 8, 2023·Updated Mar 25, 2025

In Brief

A Phase 1 clinical trial evaluating Omadacycline, Vancomycin Pill, and 1 other intervention for Healthy Volunteers. Completed, enrolled 32 participants across 1 site.

Detailed Summary

The goal of this study is to assess microbiome changes associated with omadacycline vs. comparators (moxifloxacin or oral vancomycin). Using a phase I study design, healthy volunteers aged 18-40 years will be given a 10-day course of either omadacycline 450 mg days 1 and 2 followed by 300 mg PO once daily, moxifloxacin 400 mg once daily, or oral vancomycin 125 mg given four times daily. Stool will be collected at baseline, daily during therapy, and at two follow-up time periods (days 13-14 and days 30-32). DNA will be extracted from stool and used for qPCR biomass and microbial metagenomic experiments. Results from the study will provide definitive data on the microbiome effects of omadacycline versus comparator antibiotics.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 1CompletedFinished
202120222023202420252026
First PostedSep 8, 2023
Enrollment StartOct 12, 2020
Primary CompletionSep 1, 2023
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 2.8 years ago

Interventions

Omadacyclinedrug

10-day course

Vancomycin Pilldrug

10-day course

Moxifloxacindrug

10-day course